GlassScriptPhysician profile
Derek S Powell
NPI 1356650907
$16,478.02
in general payments reported to CMS, 2019-2025
39 companies · $2,940 in 2025
The $2,940 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,388 · 2020: $1,671 · 2021: $2,088 · 2022: $2,201 · 2023: $2,616 · 2024: $2,575 · 2025: $2,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,131.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,586.23 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,213.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,702.78 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $746.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $679.30 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $660.01 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $614.68 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $564.82 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $496.38 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $492.89 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $485.04 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $460.55 | 2019-2023 | Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $324.90 | 2022 | |
| Amarin Pharma, INC. | $315.86 | 2019-2022 | |
| Antares Pharma, INC. | $306.43 | 2019-2025 | Xyosted, Nocdurna, Tlando |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $201.83 | 2019-2021 | |
| Mylan Specialty L.P. | $187.12 | 2019-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $164.19 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $147.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $146.71 | 2019-2024 | |
| Verona Pharma, INC. | $142.29 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $137.65 | 2019-2024 | Eliquis, Camzyos |
| Abbott Laboratories | $98.11 | 2019-2025 | Amplatzer Amulet |
| Takeda Pharmaceuticals U.S.A., INC. | $89.45 | 2022-2024 | Trintellix |
| Lundbeck LLC | $84.42 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $69.16 | 2024-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $51.80 | 2021 | |
| Hikma Pharmaceuticals USA | $45.19 | 2019-2021 | |
| Halozyme INC | $39.37 | 2023 | |
| Viatris Specialty LLC | $38.43 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $35.66 | 2019 | |
| Eisai INC. | $27.62 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $26.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.05 | 2023 | Quviviq |
| Pulmonx Corporation | $19.56 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Azurity Pharmaceuticals, INC. | $14.84 | 2023 | Horizant |
| Sanofi-Aventis U.S. LLC | $13.68 | 2019 | |
| Biogen, INC. | $13.57 | 2024 | Skyclarys |
| Almatica Pharma LLC | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.